Korro Bio Inc
NASDAQ:KRRO

Watchlist Manager
Korro Bio Inc Logo
Korro Bio Inc
NASDAQ:KRRO
Watchlist
Price: 8.78 USD -0.23% Market Closed
Market Cap: 82.7m USD

Operating Margin

-1 282%
Current
Improving
by 937.6%
vs 3-y average of -2 219.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 282%
=
Operating Income
$-94.5m
/
Revenue
$7.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 282%
=
Operating Income
$-94.5m
/
Revenue
$7.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Korro Bio Inc
NASDAQ:KRRO
82.5m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 3 629 companies
1st percentile
-1 282%
Low
-54 647.6% — 10.3%
Typical Range
10.3% — 24.9%
High
24.9% — 2 524.7%
Distribution Statistics
the United States of America
Min -54 647.6%
30th Percentile 10.3%
Median 17.5%
70th Percentile 24.9%
Max 2 524.7%

Korro Bio Inc
Glance View

Market Cap
82.7m USD
Industry
Biotechnology

Korro Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. Korro Bio, Inc. is a biopharmaceutical company. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The firm's focus areas include the liver and central nervous system (CNS).

KRRO Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 282%
=
Operating Income
$-94.5m
/
Revenue
$7.4m
What is Korro Bio Inc's current Operating Margin?

The current Operating Margin for Korro Bio Inc is -1 282%, which is above its 3-year median of -2 219.7%.

How has Operating Margin changed over time?

Over the last 9 months, Korro Bio Inc’s Operating Margin has increased from -4 047.1% to -1 282%. During this period, it reached a low of -4 047.1% on Dec 31, 2024 and a high of -1 282% on Oct 30, 2025.

Back to Top